All In Biotech

Drug Trial Radar · NCT00851383

A Trial to Evaluate Ad35-GRIN/ENV HIV Vaccine in Healthy Adult Volunteers

A Phase I Placebo-controlled, Double-blinded (in Terms of Vaccine or Placebo), Randomized Dose-escalation Trial to Evaluate the Safety and Immunogenicity of Ad35-GRIN/ENV HIV Vaccine in Healthy Adult Volunteers. (IAVI B001)

Last checked: Nov 19, 2026Latest source record: Apr 25, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

56

Actual

Start

Mar 2009

Primary completion

Aug 2011

Study completion Aug 2011

Sponsor

Lead sponsor
International AIDS Vaccine InitiativeResearch network
Sponsor type
Research network
Collaborators
University of Rochester
First posted
Feb 25, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and immunogenicity of Ad35-GRIN/ENV HIV vaccine and Ad35-GRIN HIV vaccine administered intramuscularly at 0 and 6 months.

Conditions

  • HIV
  • HIV Infections

Interventions

  • Ad35-GRIN/ENVBiological

    This is a dose-escalation trial. Each group will receive the Ad35-GRIN/ENV vaccine at different dosage levels.

  • Ad35-GRINBiological

    This is a dose-escalation trial. Group D will receive the Ad35-GRIN vaccine.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety (local and systemic reactogenicity signs and symptoms, laboratory measures, and adverse events)Time frame: 18 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Rochester Medical Center

    Rochester, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.